Arthneeti
All Q2 FY27 results →
AE

Advanced Enzyme Technologies Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹264
Market cap₹3.0K Cr
P/E18.7
Updated31 Oct 2026
Read3 min read

Based on Advanced Enzyme Technologies Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Q2 FY27 EBITDA: ₹721 million, a 20% increase YoY from ₹601 million in Q2 FY26 - Q2 FY27 EBITDA Margin: 34% (explicitly stated for Q2 FY27) - Q2 FY27 Profit After Tax (PAT): ₹512 million, a 14% increase YoY from ₹447 million in Q2 FY26 - Q2 FY27 PAT Margin: 24% (explicitly stated for Q2 FY27) - Operating Profit (Profit from operations before other income, finance costs, exceptional items) for Q2 FY27: ₹612 million, a 22% YoY increase from ₹500 million in Q2 FY26

From Advanced Enzyme Technologies Ltd's Q2 FY27 earnings-call transcript · updated 31 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5).
  • EBITDA for Q2 FY27: ₹721 million, up 20% YoY from ₹601 million in Q2 FY26 (Page 13, 5).
  • PAT for Q2 FY27: ₹512 million, up 14% YoY from ₹447 million in Q2 FY26 (Page 13, 5).
  • Segment growth highlights:
  • Human Nutrition: ₹1,285 million in Q2 FY27, +6% YoY (Page 8).
  • Animal Nutrition: ₹265 million, +37% YoY (Page 9).

2 more points from Advanced Enzyme Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Related focus and growth strategies include: - Continued investment in R&D for new enzymes, probiotics, and solutions. - Inorganic expansion through acquisition of key technologies, competencies, skill-sets, client relationships, and businesses in key markets (Page 30). - Expansion of sales and marketing teams in USA, MENA, and Asian markets to strengthen geographical reach (Page 31).

2 more points from Advanced Enzyme Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Advanced Enzyme Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Advanced Enzyme Technologies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

  • Lyka Labs Ltd (Q2 FY27)

    Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs). Key results statement takeaways from Lyka Labs Ltd's Q2

  • Anuh Pharma Ltd (Q2 FY27)

    64.13 lakhs (~0.34% decline). Key results statement takeaways from Anuh Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q2 FY27 results?

Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Q2 FY27 EBITDA: ₹721 million, a 20% increase YoY from ₹601 million in Q2 FY26 - Q2 FY27 EBITDA Margin: 34% (explicitly stated for Q2 FY27) - Q2 FY27 Profit After Tax (PAT): ₹512 million, a 14% increase YoY from ₹447 million in Q2 FY26 - Q2 FY27 PAT Margin: 24% (explicitly stated for Q2 FY27) - Operating Profit (Profit from operations before other income, finance costs, exceptional items) for Q2 FY27: ₹612 million, a 22% YoY increase from ₹500 million in Q2 FY26

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 18.7 with a market cap of ₹2,952 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.